Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

被引：0

作者：

Ozaki, Shuji ^{[1
]}

Harada, Takeshi ^{[2
]}

Udaka, Kengo ^{[1
]}

Sekimoto, Etsuko ^{[1
]}

Shibata, Hironobu ^{[1
]}

Shigekiyo, Toshio ^{[1
]}

Yagi, Hikaru ^{[1
]}

Okamoto, Yasunobu ^{[2
]}

Sogabe, Kimiko ^{[2
]}

Oura, Masahiro ^{[2
]}

Fujii, Shiro ^{[2
]}

Nakamura, Shingen ^{[2
]}

Miki, Hirokazu ^{[3
]}

Kagawa, Kumiko ^{[2
]}

Abe, Masahiro ^{[2
]}

机构：

[1] Tokushima Prefectural Cent Hosp, Dept Hematol, Tokushima, Tokushima, Japan

[2] Tokushima Univ Hosp, Dept Hematol, Tokushima, Tokushima, Japan

[3] Tokushima Univ Hosp, Div Transfus Med & Cell Therapy, Tokushima, Tokushima, Japan

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-115818

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5577

引用

页数：3

共 50 条

[1] Treatment of relapsed/refractory multiple myeloma patients with lenalidomide/dexamethasone in routine clinical practice
Schwarzer, A.
Fruehauf, S.
Knigsmann, M.
Schnell, R.
Reeb, M.
Heits, F.
Tirier, C.
Prange-Krex, G.
Knauf, W.
Bachinger, A.
Weiligmann, C.
Hoppe, G.
Glasmacher, A.
Schmidt, B.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 291 - 291
[2] Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Thompson, Jennifer L.
ANNALS OF PHARMACOTHERAPY, 2013, 47 (01) : 56 - 62
[3] Management of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Novel Therapies in Routine Clinical Practice in Germany
Steinmetz, H. Tilman
Singh, Moushmi
Milce, Joseph
Haidar, Mohamad
Rieth, Achim
Lebioda, Andrea
BLOOD, 2020, 136
[4] Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany
Steinmetz, H. Tilman
Singh, Moushmi
Milce, Joseph
Haidar, Mohamad
Rieth, Achim
Lebioda, Andrea
Kohnke, Jorn
ADVANCES IN THERAPY, 2022, 39 (03) : 1247 - 1266
[5] Management of patients with Relapsed/Refractory Multiple Myeloma (RRMM) treated with novel therapies in routine clinical practice in Germany
Steinmetz, T.
Singh, M.
Milce, J.
Haidar, M.
Rieth, A.
Lebioda, A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 177 - 177
[6] Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany
H. Tilman Steinmetz
Moushmi Singh
Joseph Milce
Mohamad Haidar
Achim Rieth
Andrea Lebioda
Jörn Kohnke
Advances in Therapy, 2022, 39 : 1247 - 1266
[7] Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma
Tosi, P
Zamagni, E
Cellini, C
Ronconi, S
Patriarca, F
Ballerini, F
Musto, P
Di Raimondo, F
Ledda, A
Lauria, F
Masini, L
Gobbi, M
Vacca, A
Ria, R
Cangini, D
Tura, S
Baccarani, M
Cavo, M
HAEMATOLOGICA, 2002, 87 (04) : 408 - 414
[8] Venetoclax salvage therapy in relapsed/refractory multiple myeloma
Steinhardt, M.
Truger, M.
Bittrich, M.
Zhou, X.
Noderer, J.
Riedhammer, C.
Xiao, X.
Gawlas, S.
Philipp, W.
Eisele, F.
Haferlach, C.
Mersi, J.
Waldschmidt, J.
Einsele, H.
Rasche, L.
Kortuem, K. M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 58 - 58
[9] Venetoclax salvage therapy in relapsed/refractory multiple myeloma
Steinhardt, Maximilian J.
Truger, Marietta
Bittrich, Max
Zhou, Xiang
Noderer, Julia
Riedhammer, Christine
Xiao, Xianghui
Gawlas, Sophia
Weis, Philipp
Eisele, Florian
Haferlach, Claudia
Mersi, Julia
Waldschmidt, Johannes
Einsele, Hermann
Rasche, Leo
Kortuem, K. Martin
HAEMATOLOGICA, 2024, 109 (03) : 979 - 981
[10] Novel Agents for Relapsed and/or Refractory Multiple Myeloma
Thomas, Sheeba K.
Richards, Tiffany A.
Weber, Donna M.
CANCER JOURNAL, 2009, 15 (06): : 485 - 493

← 1 2 3 4 5 →